AXIM Biotechnologies, the maker of CanChew Gum, has been granted a Notice of Allowance by the U.S. Patent and Trademark Office for all natural and synthetic cannabinoids in its controlled-release chewing gum products, the company announced in a press release. A Notice of Allowance is issued after the agency determines that a patent can be granted from an application, which was filed by AXIM in April 2015.
George E. Anastassov, AXIM’s CEO, said the protection gives the company “exclusive protection” in the cannabis pharmaceutical and nutraceutical market, preventing attempts by other companies from introducing rival products “with the same delivery system made with any cannabinoids.”
“This new patent is paramount for our company as it provides us with the intellectual property protection to include any of the at least 85 different cannabinoid compounds found in the cannabis plant, including CBD and THC, into our multiple cannabinoid-containing controlled-release chewing gum products,” Anastassov said in the release “Acquiring this new patent is also strategically important for AXIM’s mission to find cannabinoid-derived solutions for health conditions with no known cure.”
The company also announced that it will begin clinical trials for its THC/CBD gum, MedChew, targeted for the treatment of pain and spasticity associated with multiple sclerosis. The product is expected to gain full registration with the Food and Drug Administration.
Another AXIM product known as AX-1602, which contains the cannabinoid CBG, is already undergoing clinical trials as a psoriasis and atopic dermatitis treatment.